Andere talen Shattuck Labs, Inc.

Aandelen

STTK

US82024L1035

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 27-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,75 ^USD	-1,06%		-9,96%	-47,41%

20/06	SHATTUCK LABS, INC. : HC Wainwright ontvangt een koopadvies	ZM
17/06	SHATTUCK LABS, INC. : Citigroup ontvangt een koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Shattuck Labs : EHA 2024 Data Presentation	14/06
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients	14/06
Shattuck Labs, Inc. Announces Committee Appointments	11/06
Shattuck Labs Says FDA Grants Orphan Drug Designation to Leukemia Drug; Shares Rise	10/06
Shattuck Labs Gets FDA's Orphan Drug Status for Leukemia Treatment	10/06
Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)	10/06
Shattuck Labs, Inc. Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration for SL-172154 for the Treatment of Acute Myeloid Leukemia	10/06
Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients	06/06
Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients	06/06
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress	14/05
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of Sl-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (Hr-Mds) and Tp53 Mutant Acute Myeloid Leukemia Patients At the European Hematology Association 2024 Congress	14/05
Shattuck Labs : May 02, 2023 Shattuck Labs Corporate Presentation	02/05
Shattuck Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights	02/05
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024	09/04
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference	01/04
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors	04/03
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors	04/03
Shattuck Labs, Inc. Announces Board Appointments	04/03
Sector Update: Health Care Stocks Rising Late Afternoon	01/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Shattuck Labs, Inc.

Aandelen

STTK

US82024L1035

Andere talen

Filters